House passes Dextromethorphan Distribution Act; NACDS, CHPA applaud
WASHINGTON Both the Consumer Healthcare Products Association and the National Association of Chain Drug Stores commended the U.S. House of Representatives passing of H.R. 970, the Dextromethorphan Distribution Act of 2007, on Monday, which prohibits the distribution of raw dextromethorphan, an active ingredient commonly found in over-the-counter cough medicines, to any person other than FDA-registered producers of drugs and devices. On that point, NACDS would opt for the approach of Senate companion legislation, which would maintain the availability of bulk DXM to pharmacies for use in compounding.
“Today’s vote demonstrates the commitment of U.S. Reps. Fred Upton, R-Mich., and Rick Larsen, D-Wash. … and the bill’s 22 co-sponsors to protecting America’s youth from this serious threat,” stated Linda Suydam, CHPA president. “This bipartisan legislation is vital to protecting America’s youth from unscrupulous online pushers who willingly provide kids with the raw form of dextromethorphan as a means to get high.
“NACDS and its members are committed to the health of communities,” added Steven Anderson, NACDS president and chief executive officer. “This involves maintaining access to necessary medication and preventing the devastation and tragedy of the drug trade and drug abuse.”
NACDS’ work on this issue demonstrates a commitment to three stated priorities of the association—maintaining and advancing the ability of pharmacies to serve patients as an integral part of the health care system, preventing drug abuse and engaging on issues of importance to both the pharmacy and front-end operations of NACDS members.
To become law, the legislation will need to be passed by the House of Representatives and Senate in identical form, and be signed by the President.
Natrol creates mini-show to introduce its health-focused products for the holidays
CHATSWORTH, Calif. If the holidays stress you out, then you maybe at risk weight gain as well as unhealthy mind. Natrol is trying to combat this with showcases of its products that can combat this problem of staying healthy over the holidays.
Natrol has created “The Balancing Act,” a four-minute segment produced by Five Star Productions and features Natrol products like: Carb Intercept, 5-HTP, Melatonin Time Release and My Favorite Multiple Original Multivitamin.
The segment, which aired on the Healthy Living Channel—on Comcast, Time Warner and Dish Network—on Thursday, Oct. 11, has been posted on Natrol’s web site, www.Natrol.com, as well as on Five Star’s website.
McNeil running ads on product withdrawal
FORT WASHINGTON, Pa. As part of its voluntary recall of several nonprescription products marketed toward infant use, McNeil Consumer Healthcare is today running an advertisement in several consumer daily newspapers.
“The cough-and-cold season is here, and we have important information to share about infants’ and children’s cough-and-cold medicines,” the ad starts, noting that while the medicines are generally recognized as safe and effective when used as directed, “we have become aware of rare instances of misuse leading to accidental overdose, especially in children under the age of 2.”
“This voluntary action by McNeil Consumer Healthcare is based on the company’s long-standing commitment to the appropriate use of medications by parents and physicians,” stated Ashley McEvoy, president of McNeil Consumer Healthcare early Thursday morning. “McNeil Consumer Healthcare is committed to providing parents with safe and effective over-the-counter medications that treat their child’s cough-and-cold symptoms. In addition to taking this voluntary action, McNeil Consumer Healthcare, along with our industry partners, supports the Consumer Healthcare Products Association recommendations that were recently submitted to the Food and Drug Administration. These recommendations include label changes to OTC cough-and-cold medicines advising ‘do not use’ in children under 2 years of age. Our voluntary action in removing [these] products from the market is consistent with these recommendations.”